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In a recent study published in Cancer Cell, Bereshchenko and colleagues (2009) report a knockin mouse
model that represents the most frequently occurring biallelic combination of CEBPA mutations found in
human acute myeloid leukemia.Acute myeloid leukemia (AML), like all
malignancies, is considered to result
from the sequential acquisition of multiple
genetic lesions in a normal, likely long-
lived cell. This paradigm presents a
conundrum, however, since emerging
evidence increasingly indicates that the
leukemia stem cells (LSCs) responsible
for sustaining AML exhibit features of
downstream myeloid progenitors, cells
which under normal circumstances are
irreversibly committed to becoming termi-
nally differentiated within days to weeks
(Somervaille and Cleary, 2006; Krivtsov
et al., 2006; Taussig et al., 2008). A critical
component of the model is the presumed
requirement for self-renewal, a type of cell
division occurring in stem cells which
results in at least one daughter cell with
essentially the same extensive prolifera-
tive potential and differentiation status
as its parent. One possibility is that key
leukemia-initiating mutations occur in
hematopoietic stem cells (HSCs), the
only normal blood cells that undergo
self-renewal, resulting in a population of
preleukemic HSCs with a proliferative
and/or survival advantage over their non-
mutated counterparts. The accumulation
of further mutations in these initiated cells
over time results in full-fledged leukemia,
associated with aberrant self-renewal in
downstream myeloid progenitors. An
alternative possibility is that leukemia-
initiating mutations may directly confer
the capacity of inappropriate self-renewal
on downstream cells. A new study
(Bereshchenko et al., 2009) provides
insight into this issue by demonstrating
in a knockin mouse model that CEBPA
mutations can prime HSCs to generate
downstreammyeloid leukemia stem cells.CEBPA (CCAAT/enhancer binding pro-
tein alpha) is a leucine zipper transcription
factor (expressed as two isoforms of
either 30 kD or 42 kD) that regulates
myeloid differentiation in hematopoiesis,
as well as the differentiation of other
tissue-specific cell types in liver, fat, and
lung. It functions in part through repres-
sion of E2F and MYC activity, and its
complete absence in hematopoietic cells
induces pleiotropic effects, including a
block in myeloid differentiation accompa-
nied by profound reductions in mature
myeloid cell populations, an accumulation
of myeloblasts in the bone marrow with-
out progression to AML, and an enhanced
self-renewal capacity of HSCs (Kosch-
mieder et al., 2009).
CEBPA mutations are present in 7%–
10% of human AML and are mostly asso-
ciated with a normal karyotype. The
mutation patterns observed are generally
biallelic (70% of cases) and almost
always combine an N-terminal frameshift
mutation on one allele with a C-terminal
in-frame insertion/deletion mutation on
the other allele (Pabst and Mueller, 2007).
N-terminal mutations prohibit expression
of the 42 kD protein isoform, whereas
C-terminal mutations disrupt DNA binding
and dimerization by both isoforms
(Figure 1). The molecular mechanisms
throughwhichCEBPAmutations promote
AML are not entirely clear, although the 30
kD isoform binds and transactivates
target genes with lower efficiency than
the 42 kD isoform, suggesting that hypo-
morphic mutant alleles have an impaired
capacity to couple cell-cycle arrest to
terminal myeloid lineage differentiation.
Bereshchenko et al. generated two
knockin mutations of the mouse CEBPACell Stem Cell 5locus that correspond to each of the two
common alterations observed in human
AML samples. The ‘‘K allele’’ (a K313KK
mutation) generated a C-terminal mutant,
while the ‘‘L allele’’ (a nonsense codon in
the p42-specific region of CEBPA)
mimicked the human N-terminal mutation
(Figure 1A). To study the cell-intrinsic
potential of these CEBPA mutations to
initiate AML, the authors transplanted
fetal liver cells from K/L knockin mice
that expressed one of each of the two
mutant alleles or cells from L/L mice or
K/K mice into irradiated, wild-type recipi-
ents. Recipients in all three cohorts
succumbed to AML with a median
latency of 40–50 weeks. Four weeks
following transplantation and prior to
overt leukemia development, mice that
received K/K or K/L cells (but not those
that received L/L cells) exhibited amodest
relative expansion of the immunopheno-
typic HSC compartment, and a much
more substantial expansion of multipo-
tent progenitors (MPPs) downstream of
HSCs. Both preleukemic HSCs and
MPPs were less quiescent. Thus, the
presence of the K mutation promotes
proliferation and expansion of HSCs and
MPPs in the early stages of leukemogen-
esis, although it is unclear if the mutant
MPPs at this preleukemic stage have
already acquired unlimited self-renewal
potential.
The myeloid differentiation block
observed in the K/K AMLs, a mutation
combination not found in human AML,
appeared more profound than in the K/L
and L/L AMLs, resulting in some cases
in erythroleukemia rather than AML, a
phenotype reminiscent of that observed
in CEBPA null blood cells. Thus, there, November 6, 2009 ª2009 Elsevier Inc. 453
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Figure 1. CEBPA, Hematopoietic Stem Cells, and Acute Myeloid Leukemogenesis.
(A) CEBPA is produced as two isoforms that differ at their amino termini. Leukemia-associated mutations
(arrows) may prohibit production of the p42 isoform due to an upstream frameshift mutation (modeled by
the L allele in this study) or disrupt dimerization and DNA binding of both isoforms through in-frame inser-
tions or deletions (modeled by the K allele in this study).
(B) Two potential pathways to acute myeloid leukemogenesis. Some AML initiating mutations may accu-
mulate within and alter the properties of self-renewing hematopoietic stem cells (HSCs), whereas others
may directly confer self-renewal potential on committed downstream progenitors (e.g., granulocyte-
macrophage progenitors, GMPs). In both scenarios, the LSCs are downstream aberrantly self-renewing
progenitor cells but the cellular targets for initiating mutations are different. Secondary genetic or epige-
netic changes (dashed arrows) are required in both cases to produce fully functional leukemia stem cells
(LSCs). Circular black arrows indicate presence of self-renewal capacity.may be a critical hypomorphic range of
CEBPA activity that is leukemogenic in
humans, with either too little or too much
being insufficient to induce disease,
explaining the prevalent mutation combi-
nation observed in CEBPA mutated AML
patients.
Despite preleukemic expansion and
elevated cycling activity of the HSC and
MPP populations, the LSCs responsible
for sustaining AML did not exhibit features
of HSCs or MPPs. Rather, LSCs had a
downstream myeloid precursor immuno-
phenotype (CD117+, Sca1, Mac1+) simi-
lar to that reported previously in mice
with leukemias initiated by MLL fusion
oncogenes (Somervaille et al., 2009).
Thus, the preleukemic HSCs appear to
spawn downstream myeloid cells that
are predisposed to complete LSC conver-
sionby acquisition of secondary genetic or
epigenetic changes that remainundefined.
In addition to their proliferative expan-
sion, mutant HSCs also displayed alter-
ations in their differentiation program-
ming. Gene-expression profiling of K/L
mutant HSCs revealed that granulocyte-
macrophage gene sets were significantly
downregulated, whereas erythroid line-
age gene sets were significantly upregu-454 Cell Stem Cell 5, November 6, 2009 ª20lated, suggesting both the presence of
skewed lineage priming and that CEBPA
actively regulates expression of multiple
myeloid lineage-specific genes even in
uncommitted HSCs. This finding also
suggests that in CEBPA mutant HSCs,
the prevailing transcriptional state pre-
dicts the subsequent block in myeloid
differentiation in a downstream cell.
Thus, mutant HSCs appear primed for
leukemogenesis, ready for the acquisition
of further changes that contribute to the
generation of inappropriately self-renew-
ing downstream LSCs.
Although it is not currently clear what
potential selective advantage a single
CEBPA mutation might confer on an
HSC, this study provides support for the
model in which certain leukemia initiating
mutations have the capacity to convert
HSCs to proliferative, developmentally
skewed,preleukemicHSCs,whosedown-
stream progeny subsequently acquire the
requisite secondary genetic or epigenetic
changes necessary to become full-
fledged AML LSCs (Figure 1B). Thismodel
is somewhat reminiscent of acute blast
crisis of chronic myeloid leukemia, where
BCR-ABL-positive HSCs in the chronic
phase of the disease eventually generate09 Elsevier Inc.granulocyte-macrophage progenitors
(GMPs) with enhanced in vitro proliferative
potential in the acute phase (Jamieson
et al., 2004), and also AML1-ETO-associ-
ated AML, where the fusion oncogene
may be found expressed in the HSC
compartment for years following apparent
cureof thedisease (Miyamotoet al., 2000).
However, this priming model does not
appear to be generalized for AML patho-
genesis or necessary, since it is not
a feature of several other mouse models
of AML. For example, powerful oncogenes
such as MLL-AF9 or MOZ-TIF2 (Huntly
et al., 2004) have the capacity to confer
self-renewal directly on downstream
myeloid progenitors such as GMPs as an
alternative pathway for AML initiation. It
remains to be determined how accurately
the different mouse models reflect human
AML. A future challenge will be to identify
and isolate preleukemic and leukemic
clones from patients with AML, aiming to
compare the mutational status of these
functionally distinct populations.
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